Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population

Autores
Taverna, Mariano Javier; Martínez Larrad, María T.; Frechtel, Gustavo D.; Serrano Ríos, Manuel
Año de publicación
2011
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Objective: The metabolic syndrome (MS) is a cluster of cardiometabolic factors which predisposes to diabetes and cardiovascular disease (CVD). Early detection of high-risk individuals for MS using accurate measures of insulin resistance (IR) could improve detection and prevention of CVD and diabetes. The aim of this study was to explore the ability of LAP (lipid accumulation product), compared to traditional measures of IR, to identify MS. Design: 768 Spanish adults were recruited. MS was assessed using the revised criteria of NCEP/ATP III (National Cholesterol Education Program/Adult Treatment Panel III) and IDF (International Diabetes Federation). Measures of IR such as HOMA-IR and LAP, an index of lipid accumulation based on a combination of waist circumference and serum triglycerides, were calculated. ROC analysis was performed in order to detect the parameter with the best predictive capability for MS. Results: The prevalence of MS-NCEP/ATPIII and MS-IDF was 15.1 and 20.5% for men, respectively, and 15.4 and 17.5% for women. LAP showed the highest diagnostic accuracy for MS-NCEP/ATPIII (AUC 0.91 and 0.90 among males and females) and MS-IDF (0.88 for both males and females). This was confirmed by internal validation using 20,000 bootstrap samples. Among males and females, different LAP cutoff values exhibited high sensitivity (78-85%) and specificity (78-81%) for MS-NCEP/ATPIII and MS-IDF prediction with elevated efficiency (proportion of positives and negatives classified correctly by the test = 78-85%). Conclusions: LAP has a strong and reliable diagnostic accuracy for MS-IDF and, especially, MS-NCEP/ATPIII among nondiabetic adult females and, in particular, among males from Spain.
Fil: Taverna, Mariano Javier. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral "Profesor R. A. Margni"; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentina
Fil: Martínez Larrad, María T.. Hospital Clínico San Carlos; España
Fil: Frechtel, Gustavo D.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentina
Fil: Serrano Ríos, Manuel. Hospital Clínico San Carlos; España
Materia
Metabolic Syndrome
Insulin Resistance
Lipid Accumulation Product
Waist Circumference
Central Obesity
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/13922

id CONICETDig_468d5b49bd1747075301385d1a617401
oai_identifier_str oai:ri.conicet.gov.ar:11336/13922
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Lipid accumulation product: a powerful marker of metabolic syndrome in healthy populationTaverna, Mariano JavierMartínez Larrad, María T.Frechtel, Gustavo D.Serrano Ríos, ManuelMetabolic SyndromeInsulin ResistanceLipid Accumulation ProductWaist CircumferenceCentral Obesityhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Objective: The metabolic syndrome (MS) is a cluster of cardiometabolic factors which predisposes to diabetes and cardiovascular disease (CVD). Early detection of high-risk individuals for MS using accurate measures of insulin resistance (IR) could improve detection and prevention of CVD and diabetes. The aim of this study was to explore the ability of LAP (lipid accumulation product), compared to traditional measures of IR, to identify MS. Design: 768 Spanish adults were recruited. MS was assessed using the revised criteria of NCEP/ATP III (National Cholesterol Education Program/Adult Treatment Panel III) and IDF (International Diabetes Federation). Measures of IR such as HOMA-IR and LAP, an index of lipid accumulation based on a combination of waist circumference and serum triglycerides, were calculated. ROC analysis was performed in order to detect the parameter with the best predictive capability for MS. Results: The prevalence of MS-NCEP/ATPIII and MS-IDF was 15.1 and 20.5% for men, respectively, and 15.4 and 17.5% for women. LAP showed the highest diagnostic accuracy for MS-NCEP/ATPIII (AUC 0.91 and 0.90 among males and females) and MS-IDF (0.88 for both males and females). This was confirmed by internal validation using 20,000 bootstrap samples. Among males and females, different LAP cutoff values exhibited high sensitivity (78-85%) and specificity (78-81%) for MS-NCEP/ATPIII and MS-IDF prediction with elevated efficiency (proportion of positives and negatives classified correctly by the test = 78-85%). Conclusions: LAP has a strong and reliable diagnostic accuracy for MS-IDF and, especially, MS-NCEP/ATPIII among nondiabetic adult females and, in particular, among males from Spain.Fil: Taverna, Mariano Javier. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral "Profesor R. A. Margni"; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; ArgentinaFil: Martínez Larrad, María T.. Hospital Clínico San Carlos; EspañaFil: Frechtel, Gustavo D.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; ArgentinaFil: Serrano Ríos, Manuel. Hospital Clínico San Carlos; EspañaBioScientifica2011-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/13922Taverna, Mariano Javier; Martínez Larrad, María T.; Frechtel, Gustavo D.; Serrano Ríos, Manuel; Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population; BioScientifica; European Journal of Endocrinology; 164; 4; 4-2011; 559-5670804-4643enginfo:eu-repo/semantics/altIdentifier/url/http://www.eje-online.org/content/164/4/559info:eu-repo/semantics/altIdentifier/doi/10.1530/EJE-10-1039info:eu-repo/semantics/altIdentifier/url/http://www.eje-online.org/content/164/4/559.full.pdf+htmlinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:23:58Zoai:ri.conicet.gov.ar:11336/13922instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:23:58.882CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population
title Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population
spellingShingle Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population
Taverna, Mariano Javier
Metabolic Syndrome
Insulin Resistance
Lipid Accumulation Product
Waist Circumference
Central Obesity
title_short Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population
title_full Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population
title_fullStr Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population
title_full_unstemmed Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population
title_sort Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population
dc.creator.none.fl_str_mv Taverna, Mariano Javier
Martínez Larrad, María T.
Frechtel, Gustavo D.
Serrano Ríos, Manuel
author Taverna, Mariano Javier
author_facet Taverna, Mariano Javier
Martínez Larrad, María T.
Frechtel, Gustavo D.
Serrano Ríos, Manuel
author_role author
author2 Martínez Larrad, María T.
Frechtel, Gustavo D.
Serrano Ríos, Manuel
author2_role author
author
author
dc.subject.none.fl_str_mv Metabolic Syndrome
Insulin Resistance
Lipid Accumulation Product
Waist Circumference
Central Obesity
topic Metabolic Syndrome
Insulin Resistance
Lipid Accumulation Product
Waist Circumference
Central Obesity
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Objective: The metabolic syndrome (MS) is a cluster of cardiometabolic factors which predisposes to diabetes and cardiovascular disease (CVD). Early detection of high-risk individuals for MS using accurate measures of insulin resistance (IR) could improve detection and prevention of CVD and diabetes. The aim of this study was to explore the ability of LAP (lipid accumulation product), compared to traditional measures of IR, to identify MS. Design: 768 Spanish adults were recruited. MS was assessed using the revised criteria of NCEP/ATP III (National Cholesterol Education Program/Adult Treatment Panel III) and IDF (International Diabetes Federation). Measures of IR such as HOMA-IR and LAP, an index of lipid accumulation based on a combination of waist circumference and serum triglycerides, were calculated. ROC analysis was performed in order to detect the parameter with the best predictive capability for MS. Results: The prevalence of MS-NCEP/ATPIII and MS-IDF was 15.1 and 20.5% for men, respectively, and 15.4 and 17.5% for women. LAP showed the highest diagnostic accuracy for MS-NCEP/ATPIII (AUC 0.91 and 0.90 among males and females) and MS-IDF (0.88 for both males and females). This was confirmed by internal validation using 20,000 bootstrap samples. Among males and females, different LAP cutoff values exhibited high sensitivity (78-85%) and specificity (78-81%) for MS-NCEP/ATPIII and MS-IDF prediction with elevated efficiency (proportion of positives and negatives classified correctly by the test = 78-85%). Conclusions: LAP has a strong and reliable diagnostic accuracy for MS-IDF and, especially, MS-NCEP/ATPIII among nondiabetic adult females and, in particular, among males from Spain.
Fil: Taverna, Mariano Javier. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral "Profesor R. A. Margni"; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentina
Fil: Martínez Larrad, María T.. Hospital Clínico San Carlos; España
Fil: Frechtel, Gustavo D.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentina
Fil: Serrano Ríos, Manuel. Hospital Clínico San Carlos; España
description Objective: The metabolic syndrome (MS) is a cluster of cardiometabolic factors which predisposes to diabetes and cardiovascular disease (CVD). Early detection of high-risk individuals for MS using accurate measures of insulin resistance (IR) could improve detection and prevention of CVD and diabetes. The aim of this study was to explore the ability of LAP (lipid accumulation product), compared to traditional measures of IR, to identify MS. Design: 768 Spanish adults were recruited. MS was assessed using the revised criteria of NCEP/ATP III (National Cholesterol Education Program/Adult Treatment Panel III) and IDF (International Diabetes Federation). Measures of IR such as HOMA-IR and LAP, an index of lipid accumulation based on a combination of waist circumference and serum triglycerides, were calculated. ROC analysis was performed in order to detect the parameter with the best predictive capability for MS. Results: The prevalence of MS-NCEP/ATPIII and MS-IDF was 15.1 and 20.5% for men, respectively, and 15.4 and 17.5% for women. LAP showed the highest diagnostic accuracy for MS-NCEP/ATPIII (AUC 0.91 and 0.90 among males and females) and MS-IDF (0.88 for both males and females). This was confirmed by internal validation using 20,000 bootstrap samples. Among males and females, different LAP cutoff values exhibited high sensitivity (78-85%) and specificity (78-81%) for MS-NCEP/ATPIII and MS-IDF prediction with elevated efficiency (proportion of positives and negatives classified correctly by the test = 78-85%). Conclusions: LAP has a strong and reliable diagnostic accuracy for MS-IDF and, especially, MS-NCEP/ATPIII among nondiabetic adult females and, in particular, among males from Spain.
publishDate 2011
dc.date.none.fl_str_mv 2011-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/13922
Taverna, Mariano Javier; Martínez Larrad, María T.; Frechtel, Gustavo D.; Serrano Ríos, Manuel; Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population; BioScientifica; European Journal of Endocrinology; 164; 4; 4-2011; 559-567
0804-4643
url http://hdl.handle.net/11336/13922
identifier_str_mv Taverna, Mariano Javier; Martínez Larrad, María T.; Frechtel, Gustavo D.; Serrano Ríos, Manuel; Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population; BioScientifica; European Journal of Endocrinology; 164; 4; 4-2011; 559-567
0804-4643
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.eje-online.org/content/164/4/559
info:eu-repo/semantics/altIdentifier/doi/10.1530/EJE-10-1039
info:eu-repo/semantics/altIdentifier/url/http://www.eje-online.org/content/164/4/559.full.pdf+html
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv BioScientifica
publisher.none.fl_str_mv BioScientifica
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614236069691392
score 13.070432